基于顺铂的同步放化疗治疗喉鳞状细胞癌后急性髓系白血病完全缓解
Complete Remission of Acute Myeloid Leukemia following Cisplatin Based Concurrent Therapy with Radiation for Squamous Cell Laryngeal Cancer.
作者信息
Mody Mayur D, Gill Harpaul S, Higgins Kristin A, Saba Nabil F, Kota Vamsi K
机构信息
Department of Internal Medicine, Emory University School of Medicine, Atlanta, GA 30322, USA.
Department of Radiation Oncology, Emory University, Atlanta, GA 30322, USA; Winship Cancer Institute of Emory University, Atlanta, GA 30322, USA.
出版信息
Case Rep Hematol. 2016;2016:8581421. doi: 10.1155/2016/8581421. Epub 2016 Apr 3.
Abstract
Acute myeloid leukemia (AML) is a myeloid disorder with several established treatment regimens depending on patient and leukemic factors. Cisplatin is known to have strong leukemogenic potential and is rarely used even as salvage therapy in relapsed or refractory AML. We present a patient simultaneously diagnosed with AML and squamous cell carcinoma of the larynx, who was found to be in complete remission from AML following treatment with cisplatin based chemoradiotherapy for his laryngeal cancer.
摘要
急性髓系白血病（AML）是一种髓系疾病，根据患者和白血病因素有几种既定的治疗方案。已知顺铂具有很强的致白血病潜力，即使在复发或难治性AML的挽救治疗中也很少使用。我们报告了一名同时被诊断为AML和喉鳞状细胞癌的患者，在用基于顺铂的放化疗治疗其喉癌后，发现其AML完全缓解。
相似文献
1
Complete Remission of Acute Myeloid Leukemia following Cisplatin Based Concurrent Therapy with Radiation for Squamous Cell Laryngeal Cancer.
Case Rep Hematol. 2016;2016:8581421. doi: 10.1155/2016/8581421. Epub 2016 Apr 3.
2
Effective salvage therapy for high-risk relapsed or refractory acute myeloid leukaemia with cisplatin in combination with high-dose cytarabine and etoposide.
Eur J Haematol. 2014 Jun;92(6):478-84. doi: 10.1111/ejh.12274. Epub 2014 Mar 27.
3
High-dose cytarabine as salvage therapy for relapsed or refractory acute myeloid leukemia--is more better or more of the same?
Hematol Oncol. 2016 Mar;34(1):28-35. doi: 10.1002/hon.2191. Epub 2015 Feb 17.
4
Long-term follow-up and salvage surgery in patients with T2N0M0 squamous cell carcinoma of the glottic larynx following concurrent chemoradiation therapy with cisplatin and 5-fluorouracil for laryngeal preservation.
Acta Otolaryngol. 2013 Jan;133(1):91-8. doi: 10.3109/00016489.2012.715372. Epub 2012 Oct 29.
5
Modified cladribine, cytarabine, and G-CSF as a salvage regimen in patients with relapsed/refractory acute myeloid leukemia: a bridge to myeloablative allogeneic hematopoietic stem cell transplantation.
Ann Hematol. 2019 Sep;98(9):2073-2080. doi: 10.1007/s00277-019-03723-w. Epub 2019 Jun 14.
6
FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients.
Clin Lymphoma Myeloma Leuk. 2017 Nov;17(11):767-773. doi: 10.1016/j.clml.2017.06.002. Epub 2017 Jun 19.
7
Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
Clin Transl Oncol. 2018 Jul;20(7):870-880. doi: 10.1007/s12094-017-1798-8. Epub 2017 Nov 27.
8
Time sequential chemotherapy for primary refractory or relapsed adult acute myeloid leukemia: results of the phase II Gemia protocol.
Haematologica. 1999 Mar;84(3):226-30.
9
Allogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy.
Bone Marrow Transplant. 2017 Aug;52(8):1083-1090. doi: 10.1038/bmt.2017.8. Epub 2017 Feb 27.
10
[Treatment of relapsed or refractory acute myeloid leukemia].
Rinsho Ketsueki. 2017;58(10):1895-1904. doi: 10.11406/rinketsu.58.1895.
引用本文的文献
1
Collaboration of mutation in the oncogenesis of T-lymphocytic leukemia: a comparative study.
Future Sci OA. 2024 May 15;10(1):FSO934. doi: 10.2144/fsoa-2023-0111. eCollection 2024.
2
Single-cell analysis of AIMP2 splice variants informs on drug sensitivity and prognosis in hematologic cancer.
Commun Biol. 2020 Oct 30;3(1):630. doi: 10.1038/s42003-020-01353-x.
3
Molecular Targeting and Rational Chemotherapy in Acute Myeloid Leukemia.
J Exp Pharmacol. 2020 May 29;12:107-128. doi: 10.2147/JEP.S254334. eCollection 2020.
本文引用的文献
1
Synergistic cytotoxicity from combination of imatinib and platinum-based anticancer drugs specifically in Bcr-Abl positive leukemia cells.
J Pharmacol Sci. 2015 Dec;129(4):210-5. doi: 10.1016/j.jphs.2015.10.008. Epub 2015 Nov 6.
2
Molecular mechanisms of cisplatin cytotoxicity in acute promyelocytic leukemia cells.
Oncotarget. 2015 Dec 1;6(38):40734-46. doi: 10.18632/oncotarget.5754.
3
In vitro toxicity assay of cisplatin on mouse acute lymphoblastic leukaemia and spermatogonial stem cells.
Andrologia. 2016 Jun;48(5):584-94. doi: 10.1111/and.12490. Epub 2015 Oct 1.
4
5
Persistence of cisplatin-induced mutagenicity in hematopoietic stem cells: implications for secondary cancer risk following chemotherapy.
Toxicol Sci. 2014 Aug 1;140(2):307-14. doi: 10.1093/toxsci/kfu078. Epub 2014 May 5.
6
Effective salvage therapy for high-risk relapsed or refractory acute myeloid leukaemia with cisplatin in combination with high-dose cytarabine and etoposide.
Eur J Haematol. 2014 Jun;92(6):478-84. doi: 10.1111/ejh.12274. Epub 2014 Mar 27.
7
Temozolomide and cisplatin in relapsed/refractory acute leukemia.
J Hematol Oncol. 2009 May 22;2:21. doi: 10.1186/1756-8722-2-21.
8
Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics.
Curr Opin Hematol. 2005 Jan;12(1):68-75. doi: 10.1097/01.moh.0000149608.29685.d1.
9
Cisplatin: mode of cytotoxic action and molecular basis of resistance.
Oncogene. 2003 Oct 20;22(47):7265-79. doi: 10.1038/sj.onc.1206933.
10
Is cisplatin-induced cell death always produced by apoptosis?
Mol Pharmacol. 2001 Apr;59(4):657-63. doi: 10.1124/mol.59.4.657.
Zotero 插件